SOLIGENIX receives positive EMA opinion for SGX945 orphan drug designation Feb 26, 2026 07:32AM
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease Feb 26, 2026 07:30AM
Soligenix to Present at BIO Investment & Growth Summit Feb 24, 2026 07:30AM
Soligenix publishes phase 2 trial results for SGX945 in Behçet's disease Dec 18, 2025 07:30AM
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) Dec 18, 2025 07:30AM
View Older Stories

Dec 17, 2025 07:30AM Soligenix reports phase 2a psoriasis trial results for SGX302
Dec 17, 2025 07:30AM Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Nov 19, 2025 07:30AM Soligenix hits enrollment target for HyBryte lymphoma trial interim analysis
Nov 19, 2025 07:30AM Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Nov 7, 2025 07:30AM Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
Oct 14, 2025 07:30AM Soligenix updates medical advisory board for lymphoma drug development
Oct 14, 2025 07:30AM Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
Oct 7, 2025 07:30AM Soligenix reports positive safety review for phase 3 CTCL trial
Oct 7, 2025 07:30AM Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Sep 30, 2025 07:30AM Soligenix expands European medical board for lymphoma drug approval push
Sep 30, 2025 07:30AM Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Sep 29, 2025 04:05PM Soligenix completes $7.5 million public offering with warrants
Sep 29, 2025 04:05PM Soligenix Announces Closing of $7.5 Million Public Offering
Sep 26, 2025 06:34AM Soligenix prices $7.5 million public offering at $1.35 per share
Sep 26, 2025 06:33AM Soligenix Announces Pricing of $7.5 Million Public Offering
Sep 23, 2025 07:30AM Soligenix names former White House adviser Philipson as strategic advisor
Sep 23, 2025 07:30AM Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
Sep 4, 2025 07:31AM Soligenix vaccine study shows 2-year stability at high temperatures
Sep 4, 2025 07:30AM Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
Sep 2, 2025 07:30AM Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 18, 2025 07:30AM Soligenix receives FDA orphan drug designation for Behçet's disease
Aug 18, 2025 07:30AM FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
Aug 14, 2025 07:30AM Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
Jul 31, 2025 07:30AM Soligenix SGX945 shows efficacy in Behçet's disease phase 2 trial
Jul 31, 2025 07:30AM Soligenix reports positive phase 2 trial results for Behçet's disease drug
Jul 31, 2025 07:30AM Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
Jul 1, 2025 07:30AM Soligenix (SNGX) Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Jul 1, 2025 07:30AM Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Jun 6, 2025 09:37AM Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
May 9, 2025 07:30AM Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
Apr 14, 2025 07:30AM Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
Mar 25, 2025 07:32AM Soligenix, Inc. (SNGX) Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 Variants
Mar 25, 2025 07:30AM Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
Mar 21, 2025 07:31AM Soligenix (SNGX) Provides Update on Recent Accomplishments, Reports FY24 Results
Mar 21, 2025 07:30AM Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results
Mar 6, 2025 07:30AM HyBryte™ Treatment Studies Presented at Two Medical Conferences in March
Feb 4, 2025 07:30AM Soligenix to Present at BIO CEO & Investor Conference
Jan 16, 2025 07:30AM Soligenix to Present at Upcoming Investor Conferences
Jan 14, 2025 07:30AM HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Dec 16, 2024 07:30AM Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Dec 2, 2024 07:30AM HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
Nov 19, 2024 07:30AM Soligenix (SNGX) Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Nov 19, 2024 07:30AM Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Nov 15, 2024 07:30AM Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
Nov 14, 2024 07:15AM Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
Nov 8, 2024 07:30AM Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results
Oct 24, 2024 07:30AM Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
Oct 22, 2024 07:31AM Soligenix (SNGX) Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Oct 22, 2024 07:30AM Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Oct 16, 2024 07:30AM Soligenix Invited to Present at Upcoming Investor Conferences
View Older Stories